Non-Hormonal Male Contraceptive Implant Shows Promise, Lasts At Least Two Years In Trials

Non-Hormonal Male Contraceptive Implant Shows Promise, Lasts At Least Two Years In Trials

Biotech company Contraline is making strides in male contraception with a new implant that lasts at least two years in clinical trials.

The implant, named Adam, is a water-soluble hydrogel placed in the sperm ducts, preventing sperm from mixing with semen. In phase one of its trials, Adam successfully blocked sperm release for 24 months, with no sperm detected in the semen of two participants.

 

View this post on Instagram

 

A post shared by The Jasmine Brand (@the.jasmine.brand)

Dr. Alexander Pastuszak, Contraline’s chief medical officer, shared,

“These findings confirm that Adam can achieve the intended lifespan. We remain optimistic about its safety, efficacy, and reversibility, and its potential to give men and couples greater reproductive control.”

The implant is inserted via a 10-minute, minimally invasive procedure. No serious adverse events have been reported. Contraline has also received full regulatory approval for its phase two clinical study in Australia, set to begin in the third quarter of 2025.

Share your thoughts below.

[VIA]